Cyclo-oxygenase-2 inhibitors for chemoprevention of nonmelanoma skin cancer: Is there a role for these agents?

Journal of the American Academy of Dermatology

Volumn 68, Issue 1, 2013, Pages 173-176

  Liebman, Tracey N ^a   Stein, Jennifer A ^a   Polsky, David ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

basal cell carcinoma; cyclo oxygenase 2 inhibitors; nonmelanoma skin cancer; squamous cell carcinoma; topical celecoxib

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PLACEBO; ROFECOXIB;

ACTINIC KERATOSIS; ADENOMATOUS POLYP; BASAL CELL CARCINOMA; CANCER PREVENTION; CHEMOPROPHYLAXIS; COLON CANCER; COLORECTAL ADENOMA; COLORECTAL POLYP; DRUG SAFETY; DRUG WITHDRAWAL; FAMILIAL ADENOMATOUS POLYPOSIS; HUMAN; NON MELANOMA SKIN CANCER; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; THROMBOSIS;

EID: 84870862540     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2012.06.037     Document Type: Editorial

References (34)

1. A.P. Pentland Cyclooxygenase inhibitors for skin cancer prevention: are they beneficial enough? Arch Dermatol 138 2002 823 824
2. X.F. Xu, C.G. Xie, X.P. Wang, J. Liu, Y.C. Yu, and H.L. Hu Selective inhibition of cyclooxygenase-2 suppresses the growth of pancreatic cancer cells in vitro and in vivo Tohoku J Exp Med 215 2008 149 157
3. J.L. Masferrer, K.M. Leahy, A.T. Koki, B.S. Zweifel, S.L. Settle, and B.M. Woerner Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors Cancer Res 60 2000 1306 1311
4. Y.Y. Kim, E.J. Lee, Y.K. Kim, S.M. Kim, J.Y. Park, and H. Myoung Anti-cancer effects of celecoxib in head and neck carcinoma Mol Cells 29 2010 185 194
5. D. Dhawan, B.A. Craig, L. Cheng, P.W. Snyder, S.I. Mohammed, and J.C. Stewart Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder Mol Cancer Ther 9 2010 1371 1377
6. F. Di Cello, J. Hillion, J. Kowalski, B.M. Ronnett, A. Aderinto, and D.L. Huso Cyclooxygenase inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human xenografts Mol Cancer Ther 7 2008 2090 2095
7. L. Wang, W. Chen, X. Xie, Y. He, and X. Bai Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer Exp Oncol 30 2008 42 51
8. A.T. Chan, S. Ogino, and C.S. Fuchs Aspirin and the risk of colorectal cancer in relation to the expression of COX-2 N Engl J Med 356 2007 2131 2142
9. R.E. Harris Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung Inflammopharmacology 17 2009 55 67
10. K. Maaser, P. Daubler, B. Barthel, B. Heine, B. von Lampe, and H. Stein Esophageal squamous cell neoplasia in head and neck cancer patients: up-regulation of COX-2 during carcinogenesis Br J Cancer 88 2003 1217 1222
11. Y. Higashi, T. Kanekura, and T. Kanzaki Enhanced expression of cyclooxygenase (COX)-2 in human skin epidermal cancer cells: evidence for growth suppression by inhibiting COX-2 expression Int J Cancer 86 2000 667 671
12. S.M. Fischer, H.H. Lo, G.B. Gordon, K. Seibert, G. Kelloff, and R.A. Lubet Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis Mol Carcinog 25 1999 231 240
13. I.F. Orengo, J. Gerguis, R. Phillips, A. Guevara, A.T. Lewis, and H.S. Black Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model Arch Dermatol 138 2002 751 755
14. A.P. Pentland, J.W. Schoggins, G.A. Scott, K.N. Khan, and R. Han Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition Carcinogenesis 20 1999 1939 1944
15. B.C. Wulff, J.M. Thomas-Ahner, J.S. Schick, and T.M. Oberyszyn Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosuppressive drugs Int J Cancer 126 2010 11 18
16. S.M. Fischer, C.J. Conti, J. Viner, C.M. Aldaz, and R.A. Lubet Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice Carcinogenesis 24 2003 945 952
17. M. Asgari, E. White, and M.M. Chren Nonsteroidal anti-inflammatory drug use in the prevention and treatment of squamous cell carcinoma Dermatol Surg 30 2004 1335 1342
18. G.J. Butler, R. Neale, A.C. Green, N. Pandeya, and D.C. Whiteman Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin J Am Acad Dermatol 53 2005 966 972
19. C.A. Elmets, J.L. Viner, A.P. Pentland, W. Cantrell, H.Y. Lin, and H. Bailey Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial J Natl Cancer Inst 102 2010 1835 1844
20. G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, and G.B. Gordon The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952
21. T. Higuchi, T. Iwama, K. Yoshinaga, M. Toyooka, M.M. Taketo, and K. Sugihara A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients Clin Cancer Res 9 2003 4756 4760
22. J.A. Baron, R.S. Sandler, R.S. Bresalier, H. Quan, R. Riddell, and A. Lanas A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131 2006 1674 1682
23. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston, S.D. Solomon, and K. Kim Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 2006 873 884
24. N. Arber, C.J. Eagle, J. Spicak, I. Racz, P. Dite, and J. Hajer Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 355 2006 885 895
25. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston, A. Breazna, and K. Kim Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial Cancer Prev Res (Phila) 2 2009 310 321
26. P.M. Lynch, G.D. Ayers, E. Hawk, E. Richmond, C. Eagle, and M. Woloj The safety and efficacy of celecoxib in children with familial adenomatous polyposis Am J Gastroenterol 105 2010 1437 1443
27. K.G. Lewis, and M.A. Weinstock Trends in nonmelanoma skin cancer mortality rates in the United States, 1969 through 2000 J Invest Dermatol 127 2007 2323 2327
28. P.T. Bradford, A.M. Goldstein, D. Tamura, S.G. Khan, T. Ueda, and J. Boyle Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterizes the role of DNA repair J Med Genet 48 2011 168 176
29. S. Shanley, J. Ratcliffe, A. Hockey, E. Haan, C. Oley, and D. Ravine Nevoid basal cell carcinoma syndrome: review of 118 affected individuals Am J Med Genet 50 1994 282 290
30. V.E. Kimonis, A.M. Goldstein, B. Pastakia, M.L. Yang, R. Kase, and J.J. DiGiovanna Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome Am J Med Genet 69 1997 299 308
31. J.Y. Tang, M. Aszterbaum, M. Athar, F. Barsanti, C. Cappola, and N. Estevez Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice Cancer Prev Res (Phila) 3 2010 25 34
32. T.A. Wilgus, M.S. Ross, M.L. Parrett, and T.M. Oberyszyn Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation Prostaglandins Other Lipid Mediat 62 2000 367 384
33. T.A. Wilgus, A.T. Koki, B.S. Zweifel, P.A. Rubal, and T.M. Oberyszyn Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer Mol Carcinog 38 2003 33 39
34. C. Ulrich, A. Johannsen, J. Rowert-Huber, M. Ulrich, W. Sterry, and E. Stockfleth Results of a randomized, placebo-controlled safety and efficacy study of topical diclofenac 3% gel in organ transplant patients with multiple actinic keratoses Eur J Dermatol 20 2010 482 488